An epigenetic gateway to brain tumor cell identity
Related Experiment Video
Updated: Mar 28, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
Published on: September 25, 2012
Stephen C Mack1, Christopher G Hubert1, Tyler E Miller1,2,3
1Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract:
Precise targeting of genetic lesions alone has been insufficient to extend brain tumor patient survival. Brain cancer cells are diverse in their genetic, metabolic and microenvironmental compositions, accounting for their phenotypic heterogeneity and disparate responses to therapy. These factors converge at the level of the epigenome, representing a unified node that can be disrupted by pharmacologic inhibition. Aberrant epigenomes define many childhood and adult brain cancers, as demonstrated by widespread changes to DNA methylation patterns, redistribution of histone marks and disruption of chromatin structure. In this Review, we describe the convergence of genetic, metabolic and microenvironmental factors on mechanisms of epigenetic deregulation in brain cancer. We discuss how aberrant epigenetic pathways identified in brain tumors affect cell identity, cell state and neoplastic transformation, as well as addressing the potential to exploit these alterations as new therapeutic strategies for the treatment of brain cancer.
Insights
Brain cancer treatment needs new strategies beyond genetics. Epigenetic deregulation, influenced by genetics, metabolism, and environment, offers a unified therapeutic target for brain tumors.
Area of Science:
- Neuro-oncology
- Cancer Epigenetics
- Molecular Biology
Background:
- Targeting genetic mutations alone has not improved brain tumor patient survival.
- Brain cancer exhibits significant heterogeneity due to genetic, metabolic, and microenvironmental factors.
- This heterogeneity leads to varied responses to therapies.
Purpose of the Study:
- To review how genetic, metabolic, and microenvironmental factors converge on epigenetic deregulation in brain cancer.
- To discuss the role of aberrant epigenetic pathways in brain tumor progression.
- To explore the therapeutic potential of targeting epigenetic alterations in brain cancer.
Main Methods:
- Review of current literature on brain cancer epigenetics.
- Analysis of how epigenetic mechanisms contribute to tumor heterogeneity.
- Discussion of pharmacologic inhibition of epigenetic pathways.
Main Results:
- Aberrant epigenomes, including DNA methylation changes and histone modifications, are hallmarks of brain cancers.
- Epigenetic deregulation impacts cell identity, cell state, and neoplastic transformation.
- These epigenetic alterations represent a unified node for therapeutic intervention.
Conclusions:
- Epigenetic dysregulation is a central mechanism in brain cancer development and progression.
- Targeting epigenetic pathways offers a promising therapeutic strategy to overcome treatment resistance and improve patient outcomes.
- Further research into epigenetic vulnerabilities could lead to novel brain cancer therapies.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
The Tumor Microenvironment
The Tumor Microenvironment
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...

